Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol

@article{Day2007ClinicalPA,
  title={Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol},
  author={Richard Osborne Day and Garry G Graham and Mark Hicks and Andrew J. McLachlan and Sophie Lena Stocker and Kenneth Mapson Williams},
  journal={Clinical Pharmacokinetics},
  year={2007},
  volume={46},
  pages={623-644}
}
Allopurinol is the drug most widely used to lower the blood concentrations of urate and, therefore, to decrease the number of repeated attacks of gout. Allopurinol is rapidly and extensively metabolised to oxypurinol (oxipurinol), and the hypouricaemic efficacy of allopurinol is due very largely to this metabolite.The pharmacokinetic parameters of allopurinol after oral dosage include oral bioavailability of 79 ± 20% (mean ± SD), an elimination half-life (t1/2) of 1.2 ± 0.3 hours, apparent oral… 

The population pharmacokinetics of allopurinol and oxypurinol in patients with gout

TLDR
The pharmacokinetic model provides a means of predicting the allopur inol dose required to achieve target oxypurinol plasma concentrations for patients with different magnitudes of renal function, different body mass and with or without concomitant diuretic use.

Pharmacokinetics and comparative bioavailability of allopurinol formulations in healthy subjects

TLDR
The two allopurinol formulations were considered bioequivalent, based on the rate and extent of absorption, and both formulations were well tolerated.

Pharmacokinetic and Pharmacodynamic Interaction Between Allopurinol and Probenecid in Patients with Gout

TLDR
Coadministration of allopurinol with probenecid had a significantly greater hypouricemic effect than alloporinol alone despite an associated reduction of plasma oxypurinols concentrations.

Pharmacokinetic and Pharmacodynamic Interaction between Allopurinol and Probenecid in Healthy Subjects

TLDR
Coadministration of allopurinol and probenecid to healthy subjects had a greater hypouricaemic effect than either alloporinol or probenacid alone, despite a reduction in plasma oxypurinl concentrations when the drugs were taken concomitantly.

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat

TLDR
The pharmacokinetic parameters of febuxostat after multiple oral dose administration are not affected by mild to moderate hepatic impairment, and there is no consensus on whether renal impairment has any effect on the pharmacokinetics of feBUXostat.

The pharmacokinetics of oxypurinol in people with gout.

TLDR
This first established pharmacokinetic model provides a tool to achieve target oxypurinol plasma concentrations, thereby optimizing the effectiveness and safety of allopur inol therapy in gouty patients with various degrees of renal impairment.

Optimizing Therapy With Allopurinol: Factors Limiting Hypouricemic Efficacy

TLDR
Clinical aspects of the use of the hypouricemic drug allopurinol are examined, finding that the initial use of an anti-inflammatory drug or low-dose colchicine decreases but does not eliminate the development of acute attacks of gout during the initiation of therapy with allopURinol.

Individualising the dose of allopurinol in patients with gout

TLDR
Using the nomogram, the maintenance dose of allopurinol estimated to reach target concentrations can be predicted from UP, unlike previous studies which required CLCR or diuretic use as covariates to be included.

Allopurinol: insights from studies of dose–response relationships

TLDR
This review covers the metabolism and pharmacokinetics of allopurinol and its active metabolite, oxypur inol and how these factors affect the plasma concentrations of urate at initiation and during long-term therapy with allopURinol.

Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates

TLDR
The dosing regimen applied in the ALBINO trial leads to the targeted XO inhibition in neonates treated with or without TH, and their effects on inhibiting conversions of hypoxanthine and xanthine to uric acid, were assessed using nonlinear mixed-effects modelling.
...

References

SHOWING 1-10 OF 90 REFERENCES

Clinical Pharmacokinetics of Allopurinol

TLDR
The interaction of allopurinol with oral anticoagulants and phenytoin has not been clearly established in clinical practice, and dosages should be adjusted in patients with renal dysfunction.

Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.

TLDR
Although allopur inol elimination is not reduced in the aged, that of its active metabolite oxipurinol is because of an age-dependent decline in renal function.

Kinetics of allopurinol after single intravenous and oral doses

TLDR
It was concluded that about 10% of the oral dose was not absorbed and that 12% was eliminated by an unknown mechanism, presumably as riboside, in 6 healthy volunteers after a single intravenous or oral dose of allopurinol.

[The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].

TLDR
The range of 17-21 h is discussed as the most frequent oxipurinol half-life, which is prolonged under steady state conditions to 19.7 +/- 5.8 h.

Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone

TLDR
The pharmacokinetic parameters of allopurinol were not modified by the uricosuric therapy, but those of oxipur inol were markedly altered by concurrent administration even of the lower dose of benzbromarone.

Allopurinol kinetics and bioavailability

TLDR
Current use of rectal dosage forms as an adjunct in cancer chemotherapy should be re-examined because of the low systemic bioavailability of the oral tablet and the rectal suppository.

Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects

TLDR
Both in normal individuals and in patients with normal renal clearance of uric acid the effect of hydrochlorothiazide on the plasma concentration and renal excretion of oxipurinol is small, and when taking both drugs there is no increased risk during long-term treatment, and a risk is even questionable during the first days.

Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects

TLDR
The kinetics of allopurinol and hydrochlorothiazide were investigated in seven healthy male subjects during prolonged coadministration of two drugs with small difference in AUC0–24 values, which do not explain the increase in plasma uric acid concentration during hydrochlorothsiazide treatment.

Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects.

TLDR
1MU/1MX ratio appeared to be a reliable index of xanthine oxidase activity in vivo as the C50 for oxypurinol observed for 1MU/ 1MX ratio, plasma urate concentration and urine urate excretion rate were similar.

The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout

TLDR
Allomaron® was superior to allopurinol alone in lowering serum uric acid, probably because of the added uricosuric effect of benzbromarone.
...